TABLE I.
Demographic and Scanner Information for the 8 Cohorts used in this Study. Abbreviations: yrs, years; M, male; F, female; CON, control; PD, Parkinson’s disease; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; MRI, magnetic resonance imaging; TR; repetition time; UF1, University of Florida cohort 1; UF2, University of Florida cohort 2; PSHMC, Penn State Hershey Medical Center; MUI, Medical University Innsbruck; NW, Northwestern University; UM, University of Michigan; PPMI, Parkinson’s Progression Marker’s Initiative; 4RTNI, 4 Repeat Tauopathy Neuroimaging Initiative Cohort. As the PPMI cohort had variable TR times, the median is reported. Data was obtained in 3 different countries. Data are represented as mean (standard deviation) where appropriate.
| Cohort | UF1 | UF2 | PSHMC | MUI | NW | UM | PPMI | 4RTNI | Total/Average |
|---|---|---|---|---|---|---|---|---|---|
| Subjects | 169 | 100 | 104 | 180 | 55 | 206 | 150 | 38 | 1002 |
| Control/PD/MSA/PSP | 46/59/32/32 | 11/72/9/8 | 36/35/15/18 | 48/91/20/21 | 12/24/7/12 | 76/130/-/- | 49/100/1/- | -/-/-/38 | 278/511/84/129 |
| Age (yrs) | 65·24 (9·20) | 65·22 (7·92) | 70·68 (8·15) | 63·46 (10·57) | 67·25 (7·58) | 65·61 (9·34) | 59·96 (9·69) | 69·76 (7·60) | 65·05 (9·65) |
| Sex (M/F) | 98/71 | 58/42 | 68/36 | 106/74 | 30/25 | 130/76 | 99/51 | 19/19 | 608/394 |
| Start of Accrual Date (MM/DD/YY) | 01/31/12 | 04/13/17 | 11/24/09 | 07/27/11 | 11/16/17 | 12/09/08 | 10/27/10 | 06/21/11 | - |
| End of Accrual (MM/DD/YY) | 09/18/14 | 11/29/18 | 08/25/15 | 04/04/13 | 11/29/18 | 06/18/14 | 05/28/13 | 12/15/14 | - |
| Control Disease Duration (yrs) | - | - | - | - | - | - | - | - | - |
| PD Disease Duration (yrs) | 3·22 (2·34) | 2·56 (2·39) | 3·37 (3·61) | 6·02 (4·27) | 4·05 (2·44) | 6·00 (4·21) | 0·60 (0·59) | - | 3·87 (3·84) |
| MSA Disease Duration (yrs) | 3·73 (3·05) | 2·17 (1·49) | 3·60 (3·27) | 2·03 (2·26) | 1·86 (1·85) | - | 0·20 | - | 2·94 (2·77) |
| PSP Disease Duration (yrs) | 3·15 (2·95) | 2·15 (1·59) | 2·83 (2·53) | 1·74 (1·22) | 3·60 (3·13) | - | - | 5·22 (3·88) | 3·45 (3·16) |
| Control MDS-UPDRS III | 3·07 (2·82) | 6·00 (3·10) | 6·08 (7·59) | 3·00 (7·17) | 2·92 (1·38) | 4·34 (4·96) | 0·35 (0·69) | - | 3·42 (5·26) |
| PD MDS-UPDRS III | 26·19 (10·98) | 30·72 (11·68) | 38·17 (28·42) | 36·75 (12·59) | 31·00 (13·13) | 32·60 (14·27) | 19·9 (8·92) | - | 30·15 (15·02) |
| MSA MDS-UPDRS III | 46·25 (16·88) | 64·22 (14·00) | 49·60 (19·54) | 52·48 (10·97) | 59·71 (21·87) | - | - | - | 51·13 (17·17) |
| PSP MDS-UPDRS III | 45·19 (18·56) | 55·63 (19·40) | 45·44 (24·20) | 34·02 (18·10) | 46·67 (15·75) | - | - | 33·16 (17·42) | 40·65 (19·79) |
| Sites | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 1 | 17 |
| MRI Strength and Vendor | 3T Philips | 3T Siemens | 3T Siemens | 3T Siemens | 3T Siemens | 3T Philips | 3T Siemens | 3T Siemens | - |
| Directions | 64 | 64 | 42 | 20 | 64 | 15 | 64 | 41 | - |
| B-values (s/mm2) | 0,1000 | 0,1000 | 0,1000 | 0,1000 | 0,1000 | 0,800 | 0,1000 | 0,1000 | - |
| Resolution (mm x mm x mm) | 2 × 2 × 2 | 2 × 2 × 2 | 2 × 2 × 2 | 2 × 2 × 3 | 2 × 2 × 2 | 1·75 × 1·75 × 1·75 | 2 × 2 × 2 | 2·7 × 2·7 × 2·7 | - |
| TE (ms) | 86 | 58 | 82 | 83 | 58 | 67 | 86 | 82 | - |
| TR (ms) | 7748 | 6400 | 8300 | 8200 | 6400 | 8044 | 2223 | 9200 | - |